Neuropace INC

NeuroPace announced that its RNS System PMA Supplement for idiopathic generalized epilepsy (IGE) is not approvable in its current form, with the FDA requesting additional clinical evidence.

NeuroPace stockholders elected Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026.

NeuroPace reported first quarter 2026 financial results, with total revenue reaching $22.1 million and full-year revenue guidance increased to $99-$101 million.

NeuroPace, Inc. reported record third-quarter 2025 revenue of $27.4 million, a 30% increase year-over-year, and raised its full-year 2025 revenue and gross margin guidance.

NeuroPace reported record Q2 2025 revenue of $23.5 million and increased its full-year 2025 revenue guidance to $94-$98 million, driven by RNS System sales.

NeuroPace, Inc. announced a strategic leadership transition with the appointment of Patrick F. Williams as Chief Financial Officer, succeeding Rebecca Kuhn who will move into a Senior Strategic Advisor role.

NeuroPace reported a slight revenue decrease in Q1 2026 compared to the prior year, primarily due to the termination of a distribution agreement, but saw a significant improvement in gross margin.

NeuroPace, Inc. reported robust 30% revenue growth and a significant 36% reduction in net loss for Q3 2025, driven by strong RNS System sales and improved gross margins.

NeuroPace, Inc. reported a 22% revenue increase and significant gross margin expansion in Q2 2025, alongside strategic debt refinancing and progress in clinical trials for epilepsy treatments.

NeuroPace's Q1 2025 revenue increased by 24% year-over-year, driven by increased RNS System sales, while the company navigates a strategic shift with the planned expiration of its DIXI Medical distribution agreement.

NeuroPace, Inc. saw a 28% increase in revenue in the third quarter of 2024 compared to the same period last year, primarily due to increased sales of its RNS System and DIXI Medical products.

NeuroPace, Inc. announced a 21% increase in revenue for the second quarter of 2024, primarily driven by increased sales of its RNS System and DIXI Medical products.

NeuroPace's 2024 10-K filing highlights revenue growth driven by increased RNS System sales and strategic initiatives, while outlining ongoing efforts to expand market reach and address key risk factors.

NeuroPace, Inc.'s 10-K filing details the company's common stock structure, voting rights, dividend policies, and anti-takeover provisions, alongside a comprehensive overview of its business, risk factors, and regulatory landscape.

NeuroPace Inc. reports a transaction involving Chief Medical Officer Martha Morrell's beneficial ownership of common stock.

Director R. Scott Huennekens acquired 2,890 shares of common stock and options for 5,368 shares in NeuroPace, Inc.

Director Frank M. Fischer acquired 2,890 shares of common stock and 5,368 stock options as part of a compensation grant.

Director Uri Geiger acquired 2,890 shares of common stock and 5,368 stock options in NeuroPace, Inc. as part of annual compensation.

Director Rakhi Kumar acquired 2,890 shares of common stock and 5,368 stock options in NeuroPace, Inc. as part of a compensation grant.

Director Renee Ryan acquired 2,890 shares of common stock and 5,368 stock options as part of a standard equity compensation grant.

NeuroPace, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 5, 2026, to elect directors and ratify the appointment of its independent auditor.

Neuropace, Inc. has filed a definitive proxy statement with the SEC, soliciting material pursuant to Section 240.14a-12.

NeuroPace, Inc. will hold its Annual Meeting of Stockholders virtually on June 6, 2025, to elect directors and ratify the selection of PricewaterhouseCoopers LLP as its independent accounting firm.

Neuropace, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

NeuroPace, Inc. will hold its Annual Meeting of Stockholders virtually on June 7, 2024, to elect Class III directors and ratify the selection of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have filed an amendment reporting a 6.2% beneficial ownership stake in NeuroPace Inc.

Soleus Capital Management and affiliated entities report an aggregate beneficial ownership of 8.9% in NeuroPace, Inc. common stock.

KCK LTD. has reported a complete divestment of its common stock holdings in NeuroPace Inc., reducing its beneficial ownership to zero percent.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have jointly reported an 8% beneficial ownership stake in NeuroPace Inc.'s common stock.

Soleus Capital Management and its affiliates have filed an Amendment No. 5 to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in NeuroPace, Inc. common stock.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have filed an Amendment No. 5 to their Schedule 13G, confirming their continued beneficial ownership of 10.5% of NeuroPace Inc.'s common stock as of March 31, 2025.